Scholars Central

EditorialPublished 2011

Nontraditional Study Designs for Proving Bioequivalence

Authors: Sneha Latha

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

From past many years, concerns have been expressed regarding meeting the standard bioequivalence (BE) criteria for highly variable drugs. This has been point of discussion in many conferences and meetings. But to date there is no as such regulatory definition for these drugs or drug products. To pass conventional goal posts for these drugs, the number of subjects required for a study can be much higher than normally needed for a typical BE study. The resources required and the ethical concerns of exposing large number of healthy volunteers to a test drug further poses challenge to the suitability of conventional BE criteria (with an 80-125% acceptance range) for highly variable drugs. Examples exist where a highly variable reference product failed to demonstrate BE when compared to itself in a bioequivalent study using the standard design/sample size.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Sneha Latha”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels